Prostate cancer is the second most prevalent type of cancer, and the third leading cause of cancer-related deaths, in men. Early detection is key to survival, researchers said.
To screen patients for prostate cancer, medical professionals take a blood sample and look for prostate- specific antigen (PSA).
If a high level of PSA is found, the patient is suspected to have prostate cancer and required to have a prostate biopsy.
PSA tests are far from providing satisfactory diagnoses and result in a large number of unnecessary prostate biopsies due to a high false-positive rate.
"False positive diagnoses are very common in prostate cancer tests," said Jing Yong Ye, professor at The University of Texas at San Antonio (UTSA) in the US.
"As a result, a patient may undergo a biopsy he doesn't need, which is painful and could cause an infection. Also, because prostate cancer is highly heterogeneous and even multicore prostate biopsy only samples a few local areas, it can easily be missed by clinicians," said Ye.
Since about 70 per cent of men who go through the biopsy process are found to be cancer-free, Ye wanted to look for a better way.
"The system we are developing utilizes a sensitive biosensor, which allows us to distinguish cancer cells from normal cells based on a unique feature of the cells," he said.
"If you can detect a cancer cell, you're starting from a more precise place and you can give a more accurate diagnosis," he said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
